NASDAQ: NKGNNkgen Biotech Inc Stock
$1.14-0.10 (-8.06%)
Updated May 14, 2024
NKGN Price
$1.14
Fair Value Price
N/A
Market Cap
$26.00M
52 Week Low
$0.78
52 Week High
$12.88
P/E
-0.21x
P/B
-0.44x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$82.95M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.28
Operating Cash Flow
-$22M
Beta
0.3
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NKGN Overview
Graf Acquisition Corp. IV is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations. It targets companies in industries such as mobility, technology, transportation, new energy, software, business real estate services, financial and data services, healthcare, diversified industrial manufacturing, and technology. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, TX.
Zen Score
–
Industry Average (7)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NKGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NKGN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NKGN is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
NKGN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more NKGN due diligence checks available for Premium users.
Be the first to know about important NKGN news, forecast changes, insider trades & much more!
NKGN News
Valuation
NKGN fair value
Fair Value of NKGN stock based on Discounted Cash Flow (DCF)
Price
$1.14
Fair Value
-$1.27
Undervalued by
189.52%
NKGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NKGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.21x
Industry
8.12x
Market
30.29x
NKGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.44x
Industry
6.05x
NKGN's financial health
Profit margin
Revenue
$0.0
Net Income
-$33.6M
Profit Margin
0%
NKGN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$16.5M
Liabilities
$75.2M
Debt to equity
-1.28
NKGN's short-term liabilities ($39.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NKGN's long-term liabilities ($35.72M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NKGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NKGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.9M
Investing
-$18.0k
Financing
-$1.8M
NKGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NKGN vs Shell Company Stocks
Nkgen Biotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.